Prediction of promiscuous peptides that bind HLA class I molecules

被引:67
作者
Brusic, V
Petrovsky, N
Zhang, GL
Bajic, VB
机构
[1] Kent Ridge Digital Labs, Singapore 119613, Singapore
[2] Univ Canberra, Natl Bioinformat Ctr, Woden, ACT, Australia
[3] Canberra Hosp, Natl Hlth Sci Ctr, Woden, ACT, Australia
关键词
hidden Markov models; HLA allele; immunoinformatics; peptide binding; predictive modelling;
D O I
10.1046/j.1440-1711.2002.01088.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Promiscuous T-cell epitopes make ideal targets for vaccine development. We report here a computational system, multipred, for the prediction of peptide binding to the HLA-A2 supertype. It combines a novel representation of peptide/MHC interactions with a hidden Markov model as the prediction algorithm. multipred is both sensitive and specific, and demonstrates high accuracy of peptide-binding predictions for HLA-A*0201, *0204, and *0205 alleles, good accuracy for *0206 allele, and marginal accuracy for *0203 allele. multipred replaces earlier requirements for individual prediction models for each HLA allelic variant and simplifies computational aspects of peptide-binding prediction. Preliminary testing indicates that multipred can predict peptide binding to HLA-A2 supertype molecules with high accuracy, including those allelic variants for which no experimental binding data are currently available.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 38 条
[31]   Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules [J].
Sidney, J ;
Southwood, S ;
Mann, DL ;
Fernandez-Vina, MA ;
Newman, MJ ;
Sette, A .
HUMAN IMMUNOLOGY, 2001, 62 (11) :1200-1216
[32]   The potential use of peptides and vaccination to treat systemic lupus erythematosus [J].
Singh, RR .
CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (05) :399-406
[33]  
Southwood S, 1998, J IMMUNOL, V160, P3363
[34]   Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [J].
Sturniolo, T ;
Bono, E ;
Ding, JY ;
Raddrizzani, L ;
Tuereci, O ;
Sahin, U ;
Braxenthaler, M ;
Gallazzi, F ;
Protti, MP ;
Sinigaglia, F ;
Hammer, J .
NATURE BIOTECHNOLOGY, 1999, 17 (06) :555-561
[35]   MEASURING THE ACCURACY OF DIAGNOSTIC SYSTEMS [J].
SWETS, JA .
SCIENCE, 1988, 240 (4857) :1285-1293
[36]  
Threlkeld SC, 1997, J IMMUNOL, V159, P1648
[37]   T-cell-directed cancer vaccines: the melanoma model [J].
Wang, E ;
Phan, GQ ;
Marincola, FM .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (02) :277-290
[38]   Cut and trim: generating MHC class I peptide ligands [J].
Yewdell, JW ;
Bennink, JR .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (01) :13-18